Online inquiry

IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5123MR)

This product GTTS-WQ5123MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL1RAP gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001167928.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3556
UniProt ID Q9NPH3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5123MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4052MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BI 655130
GTTS-WQ13457MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PRS-343
GTTS-WQ14094MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-421
GTTS-WQ3785MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ2172MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ALT-803
GTTS-WQ7093MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FE 999301
GTTS-WQ10804MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA M777-16-3
GTTS-WQ181MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 12-IgG1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.